Vu Le

Array ( [id] => 18895249 [patent_doc_number] => 20240010734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR EGFR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/036591 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893819 [patent_doc_number] => 20240009304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => USE OF NGF ANTIBODY IN CIPN PAIN [patent_app_type] => utility [patent_app_number] => 18/036548 [patent_app_country] => US [patent_app_date] => 2021-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398211 [patent_doc_number] => 20220040301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Anti-IL-6 Antibody Formulation [patent_app_type] => utility [patent_app_number] => 17/512751 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17512751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902746 [patent_doc_number] => 20240018231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => INTRANASAL IMMUNOTHERAPT FOR THE TREATMENT OF ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/250890 [patent_app_country] => US [patent_app_date] => 2021-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548170 [patent_doc_number] => 20220119511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES, OBESITY, HYPER-CHOLESTEROLEMIA, AND ATHEROSCLEROSIS BY INHIBITION OF SAM68 [patent_app_type] => utility [patent_app_number] => 17/503113 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17503113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844545 [patent_doc_number] => 20230406949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => COMBINATORIAL IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR PANCREATIC DUCTAL ADENOCARCINOMA TREATMENT [patent_app_type] => utility [patent_app_number] => 18/248778 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380969 [patent_doc_number] => 20240270839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NOVEL ANTI-CLAUDIN18 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/246516 [patent_app_country] => US [patent_app_date] => 2021-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987818 [patent_doc_number] => 20240059787 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => HERV-K Antibody Therapeutics [patent_app_type] => utility [patent_app_number] => 18/245879 [patent_app_country] => US [patent_app_date] => 2021-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969700 [patent_doc_number] => 12338292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => CD47-CD38 bispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/478706 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 96 [patent_no_of_words] => 44745 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482232 [patent_doc_number] => 20220089736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => IMMUNE TARGETING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/472186 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18255575 [patent_doc_number] => 20230082614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => USE OF CD44 ANTIBODY IN PREPARATION OF MEDICINE FOR TREATING PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/759366 [patent_app_country] => US [patent_app_date] => 2021-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895236 [patent_doc_number] => 20240010721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => ROR1-TARGETING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/023913 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582931 [patent_doc_number] => 20230265188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA [patent_app_type] => utility [patent_app_number] => 18/043562 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -157 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770888 [patent_doc_number] => 20230365691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF NASOPHARYNGEAL CARCINOMA [patent_app_type] => utility [patent_app_number] => 18/043204 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443802 [patent_doc_number] => 20220064307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => Stable Formulations Comprising A Bispecific EGFR/C-Met Antibody [patent_app_type] => utility [patent_app_number] => 17/412346 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 237 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093144 [patent_doc_number] => 20220411485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => ANTI-APOE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/410686 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17410686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443830 [patent_doc_number] => 20220064335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => ANTI-IDIOTYPE ANTIBODIES TARGETING ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/409121 [patent_app_country] => US [patent_app_date] => 2021-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17409121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656257 [patent_doc_number] => 20230302150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/022099 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 329 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18022099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582919 [patent_doc_number] => 20230265176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ONE-ARMED ANTIGEN-BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/020656 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18020656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18567137 [patent_doc_number] => 20230257467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => PROTEINS BINDING NKG2D, CD16 AND EGFR [patent_app_type] => utility [patent_app_number] => 18/003308 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003308 [rel_patent_id] =>[rel_patent_doc_number] =>)